Loading...
Loading...
India's albendazole imports from IRELAND total $1.8K across 1 shipments from 1 foreign suppliers. NEWLIFE BIOPHARMA LIMITED leads with $1.8K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include IPCA LABORATORIES LIMITED. This corridor reflects India's pharmaceutical import demand for albendazole โ a concentrated sourcing relationship with select suppliers from IRELAND.

NEWLIFE BIOPHARMA LIMITED is the leading Albendazole supplier from IRELAND to India, with import value of $1.8K across 1 shipments. The top 5 suppliers โ NEWLIFE BIOPHARMA LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | NEWLIFE BIOPHARMA LIMITED | $1.8K | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | IPCA LABORATORIES LIMITED | $1.8K | 1 | 100.0% |
IRELAND โ India trade corridor intelligence
The Ireland to India trade corridor is currently stable, with no significant port congestion reported at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra. Freight rates have remained consistent over the past year. The exchange rate between the Euro and the Indian Rupee has shown minor fluctuations, with the Euro strengthening slightly against the Rupee.
The implementation of the PLI scheme and the Public Procurement (Preference to Make in India) Order, 2017, reflects India's push towards self-reliance and reducing import dependency. These policies may impact the volume of finished formulation imports, including those from Ireland, as they encourage domestic manufacturing and innovation.
India and Ireland maintain a strong trade relationship, with ongoing discussions to enhance pharmaceutical trade. While there is no specific Free Trade Agreement (FTA) between the two countries, both nations are members of the World Trade Organization (WTO), which facilitates trade negotiations and dispute resolutions. Mutual recognition of Good Manufacturing Practice (GMP) standards is essential for streamlining pharmaceutical trade and ensuring product quality.
The landed cost for importing finished Albendazole formulations from Ireland to India includes the following components:
The total landed duty is approximately 23.536% of the CIF value.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Albendazole into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act and associated rules is mandatory. The Directorate General of Foreign Trade (DGFT) also requires an Importer Exporter Code (IEC) for the Indian buyer to facilitate the import process.
Imported Albendazole formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Batch-wise testing is required, and a Certificate of Analysis (CoA) must accompany each shipment. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported formulations.
In April 2025, the CDSCO mandated that all imported medicines, including finished pharmaceutical formulations, must obtain import registration and licenses as per the Drugs and Cosmetics Act and associated rules. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Public Procurement (Preference to Make in India) Order, 2017, and the Production Linked Incentive (PLI) scheme have been implemented to encourage domestic manufacturing and reduce import dependency. These policies may impact the volume of finished formulation imports, including those from Ireland.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Albendazole formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic capacity may not fulfill the entire market requirement, leading to import dependency. The market size for Albendazole formulations in India is substantial, with a total export market of $72.5 million across 628 exporters to 150 countries.
The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD. The total landed duty, including all applicable taxes and surcharges, is approximately 23.536% of the Cost, Insurance, and Freight (CIF) value.
India sources finished Albendazole formulations from Ireland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Ireland's pharmaceutical industry is known for its adherence to Good Manufacturing Practice (GMP) and regulatory compliance, making it a reliable supplier. Other suppliers include China, Germany, and the United States; however, Ireland's share in the Indian market is significant due to these advantages.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Albendazole formulations from Ireland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Ireland's adherence to Good Manufacturing Practice (GMP) and regulatory compliance ensures the safety and efficacy of the products. Specific formulations supplied by Ireland, such as certain tablet strengths or combination products, may not be manufactured domestically, necessitating imports.
Compared to other origins like China, Germany, and the United States, Ireland offers competitive advantages in terms of product quality, regulatory compliance, and adherence to GMP standards. While other countries may offer lower prices, Ireland's reputation for quality and reliability makes it a preferred source for importing finished Albendazole formulations into India.
Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring currency exchange rates and staying updated on regulatory changes are also crucial for effective risk management.
Import license checklist, document requirements, quality testing, and compliance
1. Certificate of Analysis (CoA): Verify product quality and compliance.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Albendazole suppliers from IRELAND to India include NEWLIFE BIOPHARMA LIMITED. The leading supplier is NEWLIFE BIOPHARMA LIMITED with import value of $1.8K USD across 1 shipments. India imported Albendazole worth $1.8K USD from IRELAND in total across 1 shipments.
India imported Albendazole worth $1.8K USD from IRELAND across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Albendazole sourced from IRELAND include IPCA LABORATORIES LIMITED. The largest buyer is IPCA LABORATORIES LIMITED with $1.8K in imports across 1 shipments.
The total value of Albendazole imports from IRELAND to India is $1.8K USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists